Department of Microbiology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Manipal Centre for Infectious Diseases, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Ann Clin Microbiol Antimicrob. 2023 Apr 25;22(1):30. doi: 10.1186/s12941-023-00583-1.
Finegoldia magna (formerly known as Peptococcus magnus or Peptostreptococcus magnus) belonging to phylum Firmicutes, class Clostridia and genus Finegoldia, is the only species known to cause infections in human beings. Amongst Gram positive anaerobic cocci, F. magna is known to be the most virulent with a high pathogenic potential. Significant upsurge in antimicrobial resistance among anaerobes has been documented by various studies. F. magna is known to be susceptible to most of the anti-anaerobic antimicrobials, however, multidrug resistant strains are being reported in literature. The present study was undertaken to highlight the role of F. magna in clinical infections and to analyze their antimicrobial susceptibility patterns.
The present study was conducted in a tertiary care teaching hospital in Southern India. 42 clinical isolates of F. magna recovered from diverse clinical infections between January 2011 to December 2015 were studied. These isolates were subjected to antimicrobial susceptibility testing against metronidazole, clindamycin, cefoxitin, penicillin, chloramphenicol and linezolid.
Among the 42 isolates studied, majority of them were revived from diabetic foot infections (31%) followed by necrotizing fasciitis (19%) and deep-seated abscesses (19%). All the F. magna isolates showed good in-vitro activity against metronidazole, cefoxitin, linezolid and chloramphenicol. Clindamycin and penicillin resistance were observed against 9.5% and 2.4% of the isolates respectively. However, β-lactamase activity was not detected.
The antimicrobial resistance among anaerobes varies from pathogen to pathogen and region to region. Hence, a deep understanding of resistance pattern is necessary for better management of clinical infections.
大消化链球菌（以前称为巨形消化球菌或巨大消化链球菌）属于厚壁菌门、梭菌纲和消化球菌属，是已知唯一能引起人类感染的物种。在革兰阳性厌氧球菌中，大消化链球菌的毒力最强，具有很高的致病性。多项研究记录了各种厌氧菌对抗菌药物的耐药性显著上升。大消化链球菌对大多数抗厌氧抗菌药物敏感，但文献中也有报道称存在多药耐药株。本研究旨在强调大消化链球菌在临床感染中的作用，并分析其抗菌药物敏感性模式。
本研究在印度南部的一家三级保健教学医院进行。研究了 2011 年 1 月至 2015 年 12 月期间从各种临床感染中分离出的 42 株临床分离株。这些分离株进行了针对甲硝唑、克林霉素、头孢西丁、青霉素、氯霉素和利奈唑胺的抗菌药物敏感性测试。
在所研究的 42 株分离株中，大多数是从糖尿病足感染中复苏的（31%），其次是坏死性筋膜炎（19%）和深部脓肿（19%）。所有大消化链球菌分离株对甲硝唑、头孢西丁、利奈唑胺和氯霉素均显示出良好的体外活性。克林霉素和青霉素耐药性分别在 9.5%和 2.4%的分离株中观察到。然而，未检测到β-内酰胺酶活性。
不同病原体和不同地区的厌氧菌的抗菌药物耐药性存在差异。因此，深入了解耐药模式对于更好地管理临床感染非常必要。
